enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
enGene Holdings Inc. (NASDAQ: ENGN) had its price target lowered by analysts at Morgan Stanley from $37.00 to $34.00. They now have an "overweight" rating on the stock.
enGene Holdings Inc. (NASDAQ: ENGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
enGene Reports First Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]